Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter.

AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...

AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, ...

AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...

AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house ...

Modella AI, a leader in artificial intelligence for life sciences, today announced that it has been acquired by AstraZeneca, ...

Investing.com - Guggenheim has reiterated its Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) with a price target of ...

The company is embracing AI integration throughout drug development, aiming to improve efficiency and drive portfolio ...

Walmart’s addition follows its move last year to shift its stock listing from the New York Stock Exchange to Nasdaq, the ...

Walmart (WMT) stock joins the Nasdaq-100 on Jan. 20, 2026, replacing AstraZeneca (AZN) stock—potentially driving $19B in ...

On Jan. 4, 2021, a COVID-19 vaccine developed by AstraZeneca and Oxford University was administered for the first time, to an ...